PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C07D 277/48, 417/12, 417/14, 471/10, 491/10, A61K 31/426, 31/427, C07D 471/04 // (C07D 471/10, 235:00, 221:00) (C07D 491/10, 317:00, 221:00) (C07D 471/04, 235:00, 221:00)

A1

(11) International Publication Number: **WO 00/26203**

(43) International Publication Date: 11 May 2000 (11.05.00)

(21) International Application Number: PCT/EP99/08307

(22) International Filing Date: 27 October 1999 (27.10.99)

(30) Priority Data:
9823873.6 30 October 1998 (30.10.98) GB

30 Apr 01 / 30 mos

(71) Applicant *(for all designated States except US)*: PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I–20152 Milano (IT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: PEVARELLO, Paolo [IT/IT]; Piazza San Pietro in Ciel d'Oro, 7/A, I–27100 Pavia (IT). AMICI, Raffaella [IT/IT]; Via N. Rocca, 11, I–29100 Piacenza (IT). TRAQUANDI, Gabriella [IT/IT]; Via F. Cilea, 106, I–20151 Milano (IT). VILLA, Manuela [IT/IT]; Via San Bernardino, 12, I–22040 Lurago d'Erba (IT). VULPETTI, Anna [IT/IT]; Via Volturno Portici/2 80, I–20047 Brugherio (IT). ISACCHI, Antonella [IT/IT]; Via Montecatini, 14, I–20144 Milano (IT).

(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: 2–UREIDO–THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS



(I)

(57) Abstract

Compounds which are 2–ureido–1, 3–thiazole derivatives of formula (I) wherein R is a halogen atom, a nitro group, an optionally substituted amino group or it is a group, optionally further substituted, selected from: i) straight or branched C_1–C_6 alkyl; ii) C_3–C_6 cycloalkyl; iii) aryl or arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain; R_1 is an optionally substituted group selected from: i) straight or branched C_1–C_6 alkyl; ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring; iii) aryl or arylcarbonyl; iv) arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain; R_2 is hydrogen, a straight or branched C_1–C_4 alkyl or C_2–C_4 alkenyl or alkynyl group; or, taken together with the nitrogen atom to which they are bonded, R_1 and R_2 form a substituted or unsubstituted group selected from: i) an optionally benzocondensed or bridged 5 to 7 membered heterocycle; or ii) a 9 to 11 membered spiro–heterocyclic compound; or a pharmaceutically acceptable salt thereof; are useful for treating cell proliferative disorders associated with an altered cell dependent kinase activity.